Intriguingly, CDA upregulation has been found in cancer cells resistant to palbociclib (CDK 4/6 inhibitor)52, trametinib (MEK inhibitor)53, olaparib (PARP inhibitor)54, and gefitinib (EGFR inhibitor)55 (Supplementary Table 9). Here, MAP2K7 is linked to cancer.